vs
Arcellx, Inc.（ACLX）与HALOZYME THERAPEUTICS, INC.（HALO）财务数据对比。点击上方公司名可切换其他公司
HALOZYME THERAPEUTICS, INC.的季度营收约是Arcellx, Inc.的273.1倍（$451.8M vs $1.7M）。HALOZYME THERAPEUTICS, INC.净利率更高（-31.3% vs -3513.4%，领先3482.1%）。HALOZYME THERAPEUTICS, INC.同比增速更快（51.6% vs -89.2%）。HALOZYME THERAPEUTICS, INC.自由现金流更多（$217.6M vs $-58.9M）。过去两年HALOZYME THERAPEUTICS, INC.的营收复合增速更高（51.9% vs -79.5%）
Arcellx, Inc.是一家处于临床阶段的生物技术企业，专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法，其核心管线针对肿瘤领域未被满足的医疗需求，服务全球患者群体。
Halozyme Therapeutics是一家美国生物技术企业，专注于肿瘤领域创新疗法研发，核心管线均针对肿瘤微环境进行靶向干预，致力于为全球癌症患者提供更安全高效的治疗选择。
ACLX vs HALO — 直观对比
营收规模更大
HALO
是对方的273.1倍
$1.7M
营收增速更快
HALO
高出140.8%
-89.2%
净利率更高
HALO
高出3482.1%
-3513.4%
自由现金流更多
HALO
多$276.5M
$-58.9M
两年增速更快
HALO
近两年复合增速
-79.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.7M | $451.8M |
| 净利润 | $-58.1M | $-141.6M |
| 毛利率 | — | 82.6% |
| 营业利润率 | -3850.2% | -20.6% |
| 净利率 | -3513.4% | -31.3% |
| 营收同比 | -89.2% | 51.6% |
| 净利润同比 | -23.4% | -203.3% |
| 每股收益（稀释后） | $-1.01 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACLXHALO
| Q4 25 | $1.7M | $451.8M | ||
| Q3 25 | $4.9M | $354.3M | ||
| Q2 25 | $7.6M | $325.7M | ||
| Q1 25 | $8.1M | $264.9M | ||
| Q4 24 | $15.3M | $298.0M | ||
| Q3 24 | $26.0M | $290.1M | ||
| Q2 24 | $27.4M | $231.4M | ||
| Q1 24 | $39.3M | $195.9M |
净利润ACLXHALO
| Q4 25 | $-58.1M | $-141.6M | ||
| Q3 25 | $-55.8M | $175.2M | ||
| Q2 25 | $-52.8M | $165.2M | ||
| Q1 25 | $-62.3M | $118.1M | ||
| Q4 24 | $-47.1M | $137.0M | ||
| Q3 24 | $-25.9M | $137.0M | ||
| Q2 24 | $-27.2M | $93.2M | ||
| Q1 24 | $-7.2M | $76.8M |
毛利率ACLXHALO
| Q4 25 | — | 82.6% | ||
| Q3 25 | — | 84.4% | ||
| Q2 25 | — | 85.8% | ||
| Q1 25 | — | 81.7% | ||
| Q4 24 | — | 85.9% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | — | 82.9% | ||
| Q1 24 | — | 85.5% |
营业利润率ACLXHALO
| Q4 25 | -3850.2% | -20.6% | ||
| Q3 25 | -1248.3% | 61.5% | ||
| Q2 25 | -777.4% | 62.2% | ||
| Q1 25 | -847.6% | 53.4% | ||
| Q4 24 | -348.2% | 58.9% | ||
| Q3 24 | -129.1% | 56.3% | ||
| Q2 24 | -127.8% | 50.7% | ||
| Q1 24 | -40.3% | 48.8% |
净利率ACLXHALO
| Q4 25 | -3513.4% | -31.3% | ||
| Q3 25 | -1127.1% | 49.5% | ||
| Q2 25 | -698.6% | 50.7% | ||
| Q1 25 | -766.0% | 44.6% | ||
| Q4 24 | -308.4% | 46.0% | ||
| Q3 24 | -99.4% | 47.2% | ||
| Q2 24 | -99.3% | 40.3% | ||
| Q1 24 | -18.3% | 39.2% |
每股收益（稀释后）ACLXHALO
| Q4 25 | $-1.01 | $-1.13 | ||
| Q3 25 | $-0.99 | $1.43 | ||
| Q2 25 | $-0.94 | $1.33 | ||
| Q1 25 | $-1.13 | $0.93 | ||
| Q4 24 | $-0.87 | $1.06 | ||
| Q3 24 | $-0.48 | $1.05 | ||
| Q2 24 | $-0.51 | $0.72 | ||
| Q1 24 | $-0.14 | $0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $450.3M | $133.8M |
| 总债务越低越好 | — | $2.1B |
| 股东权益账面价值 | $402.4M | $48.8M |
| 总资产 | $604.0M | $2.5B |
| 负债/权益比越低杠杆越低 | — | 43.89× |
8季度趋势，按日历期对齐
现金及短期投资ACLXHALO
| Q4 25 | $450.3M | $133.8M | ||
| Q3 25 | $461.4M | $419.7M | ||
| Q2 25 | $453.1M | $61.9M | ||
| Q1 25 | $543.3M | $176.3M | ||
| Q4 24 | $587.4M | $115.8M | ||
| Q3 24 | $574.3M | $154.3M | ||
| Q2 24 | $516.7M | $187.9M | ||
| Q1 24 | $573.9M | $164.6M |
总债务ACLXHALO
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
股东权益ACLXHALO
| Q4 25 | $402.4M | $48.8M | ||
| Q3 25 | $440.8M | $503.9M | ||
| Q2 25 | $392.2M | $332.7M | ||
| Q1 25 | $416.9M | $482.3M | ||
| Q4 24 | $454.8M | $363.8M | ||
| Q3 24 | $483.0M | $452.7M | ||
| Q2 24 | $487.2M | $289.4M | ||
| Q1 24 | $496.6M | $177.8M |
总资产ACLXHALO
| Q4 25 | $604.0M | $2.5B | ||
| Q3 25 | $655.9M | $2.2B | ||
| Q2 25 | $619.1M | $2.1B | ||
| Q1 25 | $648.1M | $2.2B | ||
| Q4 24 | $711.3M | $2.1B | ||
| Q3 24 | $764.9M | $2.1B | ||
| Q2 24 | $734.3M | $2.0B | ||
| Q1 24 | $779.7M | $1.8B |
负债/权益比ACLXHALO
| Q4 25 | — | 43.89× | ||
| Q3 25 | — | 3.00× | ||
| Q2 25 | — | 4.54× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | — | 4.14× | ||
| Q3 24 | — | 3.32× | ||
| Q2 24 | — | 5.19× | ||
| Q1 24 | — | 8.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-58.2M | $219.0M |
| 自由现金流经营现金流 - 资本支出 | $-58.9M | $217.6M |
| 自由现金流率自由现金流/营收 | -3563.4% | 48.2% |
| 资本支出强度资本支出/营收 | 46.2% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-212.6M | $644.6M |
8季度趋势，按日历期对齐
经营现金流ACLXHALO
| Q4 25 | $-58.2M | $219.0M | ||
| Q3 25 | $-49.2M | $178.6M | ||
| Q2 25 | $-39.7M | $99.7M | ||
| Q1 25 | $-63.1M | $154.2M | ||
| Q4 24 | $-46.0M | $178.5M | ||
| Q3 24 | $30.7M | $115.4M | ||
| Q2 24 | $-36.2M | $55.8M | ||
| Q1 24 | $-31.9M | $129.4M |
自由现金流ACLXHALO
| Q4 25 | $-58.9M | $217.6M | ||
| Q3 25 | $-49.5M | $175.6M | ||
| Q2 25 | $-40.2M | $98.1M | ||
| Q1 25 | $-63.9M | $153.3M | ||
| Q4 24 | $-47.5M | $175.4M | ||
| Q3 24 | $28.4M | $113.9M | ||
| Q2 24 | $-39.5M | $53.2M | ||
| Q1 24 | $-38.3M | $125.9M |
自由现金流率ACLXHALO
| Q4 25 | -3563.4% | 48.2% | ||
| Q3 25 | -1000.3% | 49.6% | ||
| Q2 25 | -532.4% | 30.1% | ||
| Q1 25 | -786.4% | 57.9% | ||
| Q4 24 | -311.3% | 58.9% | ||
| Q3 24 | 109.2% | 39.3% | ||
| Q2 24 | -144.1% | 23.0% | ||
| Q1 24 | -97.7% | 64.3% |
资本支出强度ACLXHALO
| Q4 25 | 46.2% | 0.3% | ||
| Q3 25 | 6.0% | 0.9% | ||
| Q2 25 | 6.4% | 0.5% | ||
| Q1 25 | 9.6% | 0.4% | ||
| Q4 24 | 9.8% | 1.0% | ||
| Q3 24 | 8.8% | 0.5% | ||
| Q2 24 | 11.7% | 1.1% | ||
| Q1 24 | 16.4% | 1.8% |
现金转化率ACLXHALO
| Q4 25 | — | — | ||
| Q3 25 | — | 1.02× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.31× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.60× | ||
| Q1 24 | — | 1.68× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACLX
暂无分部数据
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
